Uncategorized

FDA approves first-of-its kind targeted RNA-based therapy Onpattro (patisiran) to treat a rare disease — New Drug Approvals

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease First treatment for the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adult patients The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the […]

via FDA approves first-of-its kind targeted RNA-based therapy Onpattro (patisiran) to treat a rare disease — New Drug Approvals

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s